latest news releases from the newsroom
Antisoma Reviews Portfolio: Drops AS1405 to Accelerate AS1411
LONDON, May 5, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) today announces that it plans to expand and accelerate trials of its aptamer drug AS1411, following an internal review of its portfolio. Additional investment will be supported by transferring resources from the brain cancer drug AS1405, trials of which will be suspended immediately. Antisoma's Board believes that this shift will maximise overall returns on investment in the pipeline. As AS1405 remains an attractive niche opportunity, it will be made available for out-licensing to other parties interested in pursuing its development.
Emerson Poynter LLP
Emerson Poynter LLP Announces That it Has Initiated an Investigation into American International Group, Inc. Retirement Plans -- AIG
LITTLE ROCK, Ark., May 4, 2005 (PRIMEZONE) -- Emerson Poynter LLP (www.emersonpoynter.com), a national law firm with offices in Houston, Little Rock, and Seattle, announced today that it has launched an investigation against American International Group, Inc. ("AIG" or the "Company") (NYSE:AIG) for violations of the Employee Retirement Income Security Act of 1974 ("ERISA"). The investigation focuses on investments in Company stock by the AIG Incentive Savings Plan, the American General Agents' and Managers' Thrift Plan, the American General Employees' Thrift and Incentive Plan (which was merged into the AIG Incentive Savings Plan), and the CommoLoCo Thrift Plan (the"Plans") from December 1, 1998 through the present (the "Class Period").
GulfMark Offshore, Inc.
GulfMark Offshore, Inc. Announces First Quarter 2005 Earnings Release Date and Conference Call Information
HOUSTON, May 4, 2005 (PRIMEZONE) -- GulfMark Offshore, Inc. (NASDAQ:GMRK) today announced plans to report earnings for the first quarter and three months ended March 31, 2005, after the market closes on Friday, May 6, 2005. The Company will conduct a conference call at 11:00 a.m. EDT on Monday, May 9, 2005, to discuss the results with analysts, investors and other interested parties. Individuals who wish to participate in the conference call should dial (866) 332-8507 in the United States or (816) 650-2807 from outside the country.
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2005 Financial Results
NEW YORK, May 4, 2005 (PRIMEZONE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer, today announced its financial results for the first quarter ended March 31, 2005.
Attacking Fear -- Author Offers Guidance to Combat Debilitating Emotions
NEW YORK, May 4, 2005 (PRIMEZONE) -- Negative thoughts and constant worries make it difficult to get through the day, let alone achieve one's goals in life. In his new book, Attack Your Fears with Concentration and a Positive Attitude (now available through AuthorHouse), Joshua Magloire empowers readers to conquer paralyzing thoughts and feelings that can inhibit success.